BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33349948)

  • 1. Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    Choi Y; Choi EJ; Lee JH; Lee KH; Jo JC; Park HS; Lee YJ; Seol M; Lee YS; Kang YA; Jeon M; Lee JH
    Clin Transplant; 2021 Mar; 35(3):e14199. PubMed ID: 33349948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.
    Christopeit M; Kuss O; Finke J; Bacher U; Beelen DW; Bornhäuser M; Schwerdtfeger R; Bethge WA; Basara N; Gramatzki M; Tischer J; Kolb HJ; Uharek L; Meyer RG; Bunjes D; Scheid C; Martin H; Niederwieser D; Kröger N; Bertz H; Schrezenmeier H; Schmid C
    J Clin Oncol; 2013 Sep; 31(26):3259-71. PubMed ID: 23918951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
    Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution.
    Tomonari A; Iseki T; Ooi J; Nagayama H; Sato H; Takahashi T; Ito K; Nagamura F; Uchimaru K; Takahashi S; Shirafuji N; Tojo A; Tani K; Asano S
    Int J Hematol; 2002 Apr; 75(3):318-23. PubMed ID: 11999364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation.
    Yerushalmi Y; Shem-Tov N; Danylesko I; Canaani J; Avigdor A; Yerushalmi R; Nagler A; Shimoni A
    Haematologica; 2023 Jul; 108(7):1782-1792. PubMed ID: 36475520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
    Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
    [No Abstract]   [Full Text] [Related]  

  • 7. Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion.
    Han T; Sun Y; Liu Y; Yan C; Wang Y; Xu L; Liu K; Huang X; Zhang X
    Front Med; 2021 Oct; 15(5):728-739. PubMed ID: 34279770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Swoboda R; Kulagin A; Velardi A; Sanz J; Labussière-Wallet H; Potter V; Kuball J; Sica S; Parovichnikova E; Bethge W; Maillard N; Platzbecker U; Stölzel F; Ciceri F; Mohty M
    Bone Marrow Transplant; 2023 Sep; 58(9):1008-1016. PubMed ID: 37253804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
    Kobayashi S; Kanda Y; Konuma T; Inamoto Y; Matsumoto K; Uchida N; Ikegame K; Miyamoto T; Doki N; Nakamae H; Katayama Y; Takahashi S; Shiratori S; Saito S; Kawakita T; Kanda J; Fukuda T; Atsuta Y; Kimura F
    Bone Marrow Transplant; 2022 Jan; 57(1):43-50. PubMed ID: 34625663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical
    Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
    Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis].
    Xia J; Zhao Y; Chen F; Miao M; Qiu HY; Ma X; Tang XW; Wang Y; Wu XJ; Fu ZZ; Wu DP; Chen SN
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):410-415. PubMed ID: 37032136
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor.
    Leung AY; Tse E; Hwang YY; Chan TS; Gill H; Chim CS; Lie AK; Kwong YL
    Am J Hematol; 2013 Jun; 88(6):485-91. PubMed ID: 23512868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.
    Andreola G; Labopin M; Beelen D; Chevallier P; Tabrizi R; Bosi A; Michallet M; Santarone S; Ehninger G; Polge E; Laszlo D; Schmid C; Nagler A; Mohty M
    Bone Marrow Transplant; 2015 Dec; 50(12):1508-12. PubMed ID: 26389832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
    Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
    J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
    Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
    Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors].
    Su XH; Yao JF; Zhang GX; He Y; Wei JL; Ma QL; Yang DL; Huang Y; Zhai WH; Liang C; Li G; Chen X; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1024-1030. PubMed ID: 29365394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.